COVID-19 Advanced Care

The coronavirus disease 2019 (COVID-19) pandemic, related to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden and substantial burden in public health due to an enormous increase in hospitalizations for pneumonia with the multiorgan disease. Treatm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Evangelia Fouka, Ioannis Kalomenidis, Niki Gianniou, Sofia Gida, Paschalis Steiropoulos
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	SARS-CoV-2 severe acute respiratory syndrome antiviral agents systemic corticosteroids monoclonal antibodies passive immune therapies Medicine R
Acceso en línea:	https://doaj.org/article/cdea31a1e9344c23be48713865e7bb94
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cdea31a1e9344c23be48713865e7bb94
record_format	dspace
spelling	oai:doaj.org-article:cdea31a1e9344c23be48713865e7bb942021-11-25T18:06:59ZCOVID-19 Advanced Care10.3390/jpm111110822075-4426https://doaj.org/article/cdea31a1e9344c23be48713865e7bb942021-10-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1082https://doaj.org/toc/2075-4426The coronavirus disease 2019 (COVID-19) pandemic, related to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden and substantial burden in public health due to an enormous increase in hospitalizations for pneumonia with the multiorgan disease. Treatment for individuals with COVID-19 includes best practices for supportive management of acute hypoxic respiratory failure. Emerging data indicate that dexamethasone therapy reduces 28-day mortality in patients requiring supplemental oxygen compared with usual care, and ongoing trials are testing the efficacy of antiviral therapies, immune modulators and anticoagulants in the prevention of disease progression and complications, while monoclonal antibodies and hyperimmune globulin may provide additional preventive strategies. Consensus suggestions can standardize care, thereby improving outcomes and facilitating future research. This review discusses current evidence regarding the pharmacotherapy of COVID-19.Evangelia FoukaIoannis KalomenidisNiki GianniouSofia GidaPaschalis SteiropoulosMDPI AGarticleSARS-CoV-2severe acute respiratory syndromeantiviral agentssystemic corticosteroidsmonoclonal antibodiespassive immune therapiesMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1082, p 1082 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 severe acute respiratory syndrome antiviral agents systemic corticosteroids monoclonal antibodies passive immune therapies Medicine R
spellingShingle	SARS-CoV-2 severe acute respiratory syndrome antiviral agents systemic corticosteroids monoclonal antibodies passive immune therapies Medicine R Evangelia Fouka Ioannis Kalomenidis Niki Gianniou Sofia Gida Paschalis Steiropoulos COVID-19 Advanced Care
description	The coronavirus disease 2019 (COVID-19) pandemic, related to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden and substantial burden in public health due to an enormous increase in hospitalizations for pneumonia with the multiorgan disease. Treatment for individuals with COVID-19 includes best practices for supportive management of acute hypoxic respiratory failure. Emerging data indicate that dexamethasone therapy reduces 28-day mortality in patients requiring supplemental oxygen compared with usual care, and ongoing trials are testing the efficacy of antiviral therapies, immune modulators and anticoagulants in the prevention of disease progression and complications, while monoclonal antibodies and hyperimmune globulin may provide additional preventive strategies. Consensus suggestions can standardize care, thereby improving outcomes and facilitating future research. This review discusses current evidence regarding the pharmacotherapy of COVID-19.
format	article
author	Evangelia Fouka Ioannis Kalomenidis Niki Gianniou Sofia Gida Paschalis Steiropoulos
author_facet	Evangelia Fouka Ioannis Kalomenidis Niki Gianniou Sofia Gida Paschalis Steiropoulos
author_sort	Evangelia Fouka
title	COVID-19 Advanced Care
title_short	COVID-19 Advanced Care
title_full	COVID-19 Advanced Care
title_fullStr	COVID-19 Advanced Care
title_full_unstemmed	COVID-19 Advanced Care
title_sort	covid-19 advanced care
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/cdea31a1e9344c23be48713865e7bb94
work_keys_str_mv	AT evangeliafouka covid19advancedcare AT ioanniskalomenidis covid19advancedcare AT nikigianniou covid19advancedcare AT sofiagida covid19advancedcare AT paschalissteiropoulos covid19advancedcare
_version_	1718411644826025984

COVID-19 Advanced Care

Ejemplares similares